• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Influenza Virus Vaccine for the 2006-2007 Season

Influenza Vaccine Lot Release Status

This chart provides information on flu vaccine lots that have been released by FDA. This information will be updated periodically as additional vaccine is received from manufacturers and released by FDA.

For information on flu vaccine distribution schedules, please contact the manufacturers directly.

Lots Released as of December 13, 2006

Manufacturer Total Number of Lots Released by FDA
Fluvirin
Chiron Vaccines Ltd
Gaskill Road Speke,
Liverpool, L24 9GR, UK
License 1720
48
Fluarix
GlaxoSmithKline Biologics
Rue de l'Institut 89
B1330 Rixensart Belgium
License 1617
31
FluLaval
ID Biomedical Corporation of Quebec (IDB)
Sainte-Foy, Canada
License 1739
38
FluMist
MedImmune Vaccines, Inc
297 North Bernardo Ave
Mountain View, CA 94043
License 1652
21
Fluzone
Sanofi Pasteur, Inc
Discovery Drive
Swiftwater, PA 18370
License 1725
85

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Bethesda, Maryland, on February 17, 2006, to select the influenza virus strains for the composition of the influenza vaccine for use in the 2006-2007 U.S. influenza season. During this meeting, the advisory panel reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics, serological responses to 2005/2006 vaccines, and the availability of candidate strains and reagents.

The panel recommended that vaccines to be used in the 2006-2007 season in the U.S. contain the following:

  • an A/New Caledonia/20/99 (H1N1)-like virus;
  • an A/Wisconsin/67/2005 (H3N2)-like virus (A/Wisconsin/67/2005 and A/Hiroshima/52/2005strains);
  • a B/Malaysia/2506/2004-like virus (B/Malaysia/2506/2004 and B/Ohio/1/2005 strains)

The influenza vaccine composition to be used in the 2006-2007 season in the U.S. is identical to that recommended by the World Health Organization on February 15, 2006.